AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28202475
Drug: Fiber (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber (4.8 or 9.6 g) added to standard white-bread challenge
Trial: 26415035
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc supplementation (1 mg/kg/day) for six months
Trial: 17426747
Drug: Glucose (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (25 or 50 g portions)
Trial: 16402242
Drug: Rabeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (40 mg)
Trial: 10715293
Drug: Sucralfate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1.5 g orally every 6 hours)
Trial: 1586618
Drug: CHOP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, doxorubicin 50 mg/m2, prednisone 50 mg/m2)
Trial: 1586618
Drug: CNOP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNOP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, mitoxantrone 10 mg/m2, prednisone 50 mg/m2)
Trial: 31704907
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine combining EGFR-TKI (n=92)
Trial: 31704907
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine combining EGFR-TKI for 19DEL mutant NSCLC
Trial: 31704907
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine combining EGFR-TKI for L858 mutant NSCLC
Trial: 31704907
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine combining EGFR-TKI
Trial: 24669010
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC)
Trial: 17288699
Drug: Clarithromycin immediate-release
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin immediate-release (IR) 500 mg twice daily for 7 days or telithromycin 800 mg once daily for 5 days (comparator)
Trial: 12494803
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (n = 22), 10 mg/h during 2 h then 5 mg every 4 h
Trial: 12494803
Drug: Nebulized adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized adrenaline (n = 22), 6 mg/h during 2 h then 3 mg every 4 h
Trial: 2920500
Drug: Phenylpropanolamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine infusion (0.44 mg/kg)
Trial: 1082383
Drug: TNM1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNM1 vaccine
Trial: 30958062
Drug: Caffeinated chewing
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated chewing gum (300 mg of caffeine)
Trial: 25545858
Drug: Varenicline (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (dose increased to a maximum of 5 mg/d)
Trial: 19099294
Drug: Cannabis cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis cigarettes containing 0 mg THC (placebo)
Trial: 19099294
Drug: Cannabis cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis cigarettes containing 29.3 mg THC
Trial: 19099294
Drug: Cannabis cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis cigarettes containing 49.1 mg THC
Trial: 19099294
Drug: Cannabis cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis cigarettes containing 69.4 mg THC
Trial: 16469601
Drug: Tolterodine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine (2 mg twice daily)
Trial: 15223887
Drug: Topical analgesic
RxNorm normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical analgesic
Trial: 9234921
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (cisplatin, vincristine, and bleomycin every 3 weeks for four courses)
Trial: 8215728
Drug: Nortriptyline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (50 to 150 mg/mL for 6 weeks)
Trial: 29289540
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg/d (n=67)
Trial: 29289540
Drug: Glargine at
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine at a starting dose of 0.1 U/kg/d (n=73)
Trial: 29289540
Drug: Glargine at
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine at a starting dose of 0.1 U/kg/d
Trial: 27474257
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of the proton pump inhibitor (rabeprazole)
Trial: 24743122
Drug: Standard procedure
RxNorm normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard procedure (Antibiotics, systemic metronidazole, antihistamines, traditional external therapy)
Trial: 24743122
Drug: Rutin Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rutin Forte (2 capsules per day)
Trial: 22023376
Drug: Carbohydrate intake,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate intake, insulin boluses, and bouts of exercise
Trial: 22023376
Drug: 10-min plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-min plasma glucose measurements and plasma insulin and glucagon analyses
Trial: 20123226
Drug: rt‐PA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA treatment between 0401 and 0800 hours
Trial: 20123226
Drug: rt‐PA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA treatment between 0000 and 0400 hours
Trial: 20123226
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with stroke onset between 1801 and 2400 hours
Trial: 12970212
Drug: Low-dose target
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose target range (INR 1.8 to 2.8 for aortic position and 2.5 to 3.5 for mitral position)
Trial: 31831073
Drug: SPIN-SSLED Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPIN-SSLED Program (13-module training delivered via webinar over 3 months in weekly 60-90 minute sessions)
Trial: 29074542
Drug: Inhaled RV568
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled RV568 (50 µg)
Trial: 29074542
Drug: Inhaled RV568
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled RV568 (100 µg)
Trial: 29074542
Drug: Inhaled RV568
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled RV568
Trial: 18561007
Drug: Self-Administered Interview
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Administered Interview (SAI)
Trial: 15832861
Drug: Face Former
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face Former therapy
Trial: 15832861
Drug: Conventional myofunctional
RxNorm normalized name: Bifunctional epoxide hydrolase 2
DrugBank: Bifunctional epoxide hydrolase 2 (DB15139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional myofunctional therapy (Control)
Trial: 15896747
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1,500 mg twice a day
Trial: 15896747
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 1.5 to 3 mg/kg in 4 daily doses
Trial: 8726758
Drug: NaP solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaP solution
Trial: 6758252
Drug: Three-times-weekly regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-times-weekly regimens containing isoniazid, rifampicin, and streptomycin and pyrazinamide (regimen 1)
Trial: 6758252
Drug: Three-times-weekly regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-times-weekly regimens containing isoniazid, rifampicin, and streptomycin (regimen 2)
Trial: 6758252
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol
Trial: 6758252
Drug: Three-times-weekly regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-times-weekly regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (regimen 4)
Trial: 6758252
Drug: Three-times-weekly regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-times-weekly regimen of isoniazid, rifampicin, and ethambutol (regimen 3)
Trial: 31094782
Drug: Buccal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal oxygen administration
Trial: 24735005
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine 0.4% (n=37), administered 4 times daily for 3 days before surgery and 5 weeks postoperatively.
Trial: 24735005
Drug: Hypromellose/dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypromellose/dextran 70 as a placebo (n=44), administered 4 times daily for 3 days before surgery and 5 weeks postoperatively.
Trial: 20064211
Drug: CAT-354 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAT-354 (1 mg/kg, 5 mg/kg, or 10 mg/kg)
Trial: 18330081
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin (40 mg/m2) administered intravenously at 4 week intervals
Trial: 9290119
Drug: Beta-carotene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (30 mg/day)
Trial: 30194492
Drug: BRN-01 homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRN-01 homeopathic medicine complex (Actheane®)
Trial: 29716492
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.2% ropivacaine via adductor canal catheter for five days
Trial: 29716492
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.2% ropivacaine via adductor canal catheter for three days
Trial: 26988768
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg.kg(‐1) body mass plus 0.1 g.kg(‐1) body mass sodium chloride)
Trial: 26988768
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g.kg(‐1) body mass)
Trial: 26988768
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g.kg(‐1) body mass) plus caffeine (5 mg.kg(‐1) body mass)
Trial: 26988768
Drug: Placebo (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.1 g.kg(‐1) body mass sodium chloride)
Trial: 22528506
Drug: Metoprolol formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol formulations (100 mg) - slow, moderate, and fast releasing
Trial: 22528506
Drug: Synthetic solution
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic solution method
Trial: 22528506
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution data
Trial: 19040679
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium extended-release (initiated at 500 mg/day for 15 days, then increased to 1000 mg daily, with adjustments permitted within a dosing range of 250-1000 mg daily)
Trial: 19040679
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium extended-release
Trial: 15312855
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,200 mg orally twice daily; NAC group; n = 97
Trial: 9692411
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg twice daily until delivery)
Trial: 9692411
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (nifedipine given if diastolic pressure exceeded 110 mmHg)
Trial: 24035531
Drug: BCI-L (Breast-Cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCI-L (Breast-Cancer Index - Linear)
Trial: 18171334
Drug: Intramuscular antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular antivenom (one or two vials)
Trial: 18171334
Drug: Intravenous antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antivenom (one vial or two or more vials)
Trial: 16879942
Drug: 150 ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml, 240 mg/ml at 4 ml/s
Trial: 16879942
Drug: 120 ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 ml, 300 mg/ml at 4 ml/s
Trial: 16879942
Drug: 97.3 ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 97.3 ml, 370 mg/ml at 4 ml/s
Trial: 16879942
Drug: 150 ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml, 240 mg/ml at 5 ml/s
Trial: 16879942
Drug: 120 ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 ml, 300 mg/ml, 60 ml at 6 ml/s, 60 ml at 3 ml/s
Trial: 16879942
Drug: 97.3 ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 97.3 ml, 370 mg/ml at 3.3 ml/s
Trial: 16879942
Drug: Constant iodine
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant iodine administration rates (groups II, IV and VI)
Trial: 12807165
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation powder (Pulmicort Turbuhaler), 100-800 microg b.i.d. for 52 weeks
Trial: 12807165
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation powder (Pulmicort Turbuhaler)
Trial: 8888715
Drug: Telenzepine (M1‐muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine (M1‐muscarinic receptor antagonist)
Trial: 1891575
Drug: Psychodynamic, time-limited
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic, time-limited group therapy
Trial: 20521324
Drug: Lorazepam (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (acute dose)
Trial: 8038589
Drug: Double perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double perfusion schedule with melphalan (6 mg/l limb volume for first perfusion, 9 mg/l for second perfusion, normothermic, 1 hour duration, 3-4 weeks interval)
Trial: 8038589
Drug: Single perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single perfusion procedure with melphalan (10 mg/l, normothermic, 1 hour duration)
Trial: 2498532
Drug: Intravesical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical mitomycin C (40 mg)
Trial: 949902
Drug: gefarnate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gefarnate (600 mg daily)
Trial: 949902
Drug: dummy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dummy treatment
Trial: 30531772
Drug: Venarus and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venarus and compression therapy
Trial: 19737089
Drug: PHD inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHD inhibitors
Trial: 15933281
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment implemented three times per week for 20 to 30 min each session for 3 months
Trial: 12783289
Drug: Ibandronate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (2 or 4 mg)
Trial: 12783289
Drug: Pamidronate (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (15, 30, 60, or 90 mg)
Trial: 10943910
Drug: Dextromethorphan (non-competitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (non-competitive NMDA antagonist)
Trial: 1644724
Drug: Nortriptyline (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (not specified dosage or duration)
Trial: 6131825
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active drugs (Quazepam and Flunitrazepam)
Trial: 6131825
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs tested (Quazepam and Flunitrazepam)
Trial: 25218717
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (PLA, DECAF, CAF, COF)
Trial: 27885751
Drug: Optimal Pharmacologic
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Pharmacologic Therapy (OPT)
Trial: 21142736
Drug: 810-nm diode
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 810-nm diode laser treatment
Trial: 18097896
Drug: Intramuscular ergometrine
RxNorm normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ergometrine (500 microg) during abdominal closure
Trial: 18097896
Drug: Routine bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine bolus dose of 5 units of oxytocin after delivery
Trial: 12170143
Drug: Intravenous MgSO(4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous MgSO(4) with carbogen inhalation
Trial: 11769996
Drug: Carbogen inhalation
RxNorm normalized name: carbogen Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbogen inhalation
Trial: 2893560
Drug: Intramuscular buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular buprenorphine 0.3 mg
Trial: 19464064
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg bid for four weeks (uptitrated to 125 mg bid thereafter)
Trial: 15901290
Drug: Levovist 1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levovist 1 g
Trial: 15901290
Drug: Sono Vue
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sono Vue 1 mL
Trial: 9395700
Drug: Therapeutic touch
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic touch (TT) therapy
Trial: 8388479
Drug: All-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans-retinoic acid (all-trans-RA) at a dose of 156 mg/m2 on day 28 and 78 mg/m2 on day 29.
Trial: 8388479
Drug: All-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans-retinoic acid (all-trans-RA) at a dose of 78 mg/m2 on day 28 and 156 mg/m2 on day 29.
Trial: 11449752
Drug: Family-involved treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-involved treatments
Trial: 31477086
Drug: Intensive personalized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive personalized modular outpatient treatment
Trial: 30563642
Drug: Esomeprazole and
RxNorm normalized name: Esomeprazole and naproxen only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole and Aspirin
Trial: 17103286
Drug: Ultrasound guided‐percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided‐percutaneous drainage and i.v. antibiotics (ampicillin, cefuroxime, and metronidazole)
Trial: 2683921
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (20 1-g capsules for 12 weeks)
Trial: 30326006
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 400 mg to 800 mg 3 times a day for 8 weeks